(S)-(−)-Warfarin
(S)-(−)-Warfarin structure
|
Common Name | (S)-(−)-Warfarin | ||
|---|---|---|---|---|
| CAS Number | 5543-58-8 | Molecular Weight | 308.328 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 515.2±50.0 °C at 760 mmHg | |
| Molecular Formula | C19H16O4 | Melting Point | ≥170ºC | |
| MSDS | Chinese USA | Flash Point | 188.8±23.6 °C | |
| Symbol |
GHS08 |
Signal Word | Danger | |
Use of (S)-(−)-Warfarin(+)-Warfarin is an anticoagulant that interferes with interconversion of vitamin K and vitamin K epoxide and the role of vitamin K in carboxylation of several clotting cascade proteins, inhibiting the |
| Name | (R)-warfarin |
|---|---|
| Synonym | More Synonyms |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 515.2±50.0 °C at 760 mmHg |
| Melting Point | ≥170ºC |
| Molecular Formula | C19H16O4 |
| Molecular Weight | 308.328 |
| Flash Point | 188.8±23.6 °C |
| Exact Mass | 308.104858 |
| PSA | 67.51000 |
| LogP | 3.42 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.635 |
| Symbol |
GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360D-H372-H412 |
| Precautionary Statements | P201-P273-P308 + P313 |
| Hazard Codes | T |
| Risk Phrases | 61-48/25-52/53 |
| Safety Phrases | 53-45-61 |
| RIDADR | UN 2811 6.1/PG 1 |
|
Hologram QSAR model for the prediction of human oral bioavailability.
Bioorg. Med. Chem. 15 , 7738-45, (2007) A drug intended for use in humans should have an ideal balance of pharmacokinetics and safety, as well as potency and selectivity. Unfavorable pharmacokinetics can negatively affect the clinical devel... |
|
|
Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes.
J. Thromb. Haemost. 8(12) , 2708-17, (2010) Warfarin, an antagonist of vitamin K, is an oral coumarin anticoagulant widely used to control and prevent thromboembolic disorders. Warfarin is clinically available as a racemic mixture of R- and S-w... |
|
|
Secreted protein profile from HepG2 cells incubated by S(-) and R(+) enantiomers of chiral drug warfarin - An analysis in cell-based system and clinical samples.
Proteomics. Clin. Appl. 4(10-11) , 808-15, (2010) warfarin is a commonly prescribed oral anticoagulant with narrow therapeutic index. It interferes with the vitamin K cycle to achieve anti-coagulating effects. Warfarin has two enantiomers, S(-) and R... |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]- |
| S-(−)-4-Hydroxy-3-(3-oxo-1-phenybutyl)-2H-1-benzopyran-2-one |
| 4-Hydroxy-3-[(1R)-3-oxo-1-phenylbutyl]-2H-chromen-2-one |
| Warfarin |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-[(1R)-3-oxo-1-phenylbutyl]- |
| EINECS 226-908-9 |
| (R)-Warfarin |
| 4-Hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]-2H-chromen-2-one |
| (R)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one |
| R-(+)-Warfarin |
| (-)-Warfarin |
| (S)-Warfarin |
| (R)-(+)-4-Hydroxy-3-(3-oxo-1-phenybutyl)-2H-1-benzopyran-2-one |
| MFCD00272376 |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (S)- |
| (R)-(+)-WARFARIN |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (R)- |
| (+)-Warfarin |
| (S)-(-)-Warfarin |